Mass spectrometry analysis of mutant polypeptides in biological samples

Patent metadata

Field	Value
Publication number	US-10036756-B2
Application number	US-201615245393-A
Country	US
Kind code	B2
Filing date	Aug 24, 2016
Priority date	Feb 1, 2010
Publication date	Jul 31, 2018
Grant date	Jul 31, 2018

Abstract

The invention relates to a method for determining the presence of at least one distinct polypeptide in a biological sample comprising contacting the biological sample with a hydrolyzing agent, wherein the hydrolyzing agent is capable of hydrolyzing the distinct polypeptide in a sequence-specific manner such that at least one distinct peptide having a predetermined peptide measured accurate mass would result if the at least one distinct polypeptide were present in the biological sample, to obtain a hydrolyzed sample; bringing the hydrolyzed sample in contact with a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding the distinct peptide; removing the hydrolyzed sample from the substrate in a manner such that the distinct peptide would remain bound to the immobilized binding partner; contacting the substrate with an elution solution, wherein the distinct peptide would dissociate from the immobilized binding partner into the elution solution; subjecting a portion of the elution solution to liquid chromatography to segregate a plurality of molecules in the portion of the elution solution to obtain sorted molecules; determining the measured accurate mass of at least one sorted molecule present in the elution solution; and determining the presence of the at least one distinct polypeptide in the biological sample when a measured accurate mass of at least one molecule is substantially equal to the predetermined peptide measured accurate mass.

First claim

What is claimed is:

1. A kit for determining the presence of at least one distinct polypeptide, in a biological sample, comprising a substrate comprising at least one immobilized binding partner, wherein the at least one immobilized binding partner is capable of specifically binding a distinct peptide containing a mutation or post-translational modification relative to a wild type or unmodified polypeptide, wherein the distinct polypeptide has been hydrolyzed in a sequence specific manner by a hydrolyzing agent into at least one distinct peptide and wherein the at least one distinct peptide has a predetermined peptide measured accurate mass.

2. The kit of claim 1 , further comprising at least one standard peptide, wherein the at least one standard peptide has substantially the same amino acid sequence as the at least one distinct peptide but a different peptide measured accurate mass.

3. The kit of claim 1 , further comprising at least two reference peptides, wherein the at least two reference peptides have a known liquid chromatography elution order.

4. The kit of claim 2 , wherein the standard peptide comprises an isotope selected from the group consisting of 15 N, 13 C, 18 O and 2 H.

5. The kit of claim 2 , wherein the at least one standard peptide and the at least one distinct peptide co-segregate during liquid chromatography.

6. The kit of claim 2 , wherein the at least one standard peptide and the at least one distinct peptide have a substantially identical retention time.

7. The kit of claim 1 , wherein the mutation is an addition, deletion and/or substitution of about 1 to about 10 amino acid residues.

8. The kit of claim 1 , wherein the post-translational modification is selected from the group consisting of phosphorylation, acetylation, ubiquitination, and glycosylation.

9. The kit of claim 1 , wherein the kit further comprises the hydrolyzing agent.

10. The kit of claim 9 , wherein the hydrolyzing agent is selected from the group consisting of an enzyme and a chemical.

11. The kit of claim 9 , wherein the hydrolyzing agent is selected from the group consisting of cyanogen bromide, BNPS-Skatole, formic acid, trypsin, Lysine-C endopeptidase (LysC); arginine-C endopeptidase (ArgC), Asp-N, glutamic acid, endopeptidase (GluC), chymotrypsin, and combinations thereof.

12. The kit of claim 1 , wherein the substrate comprises a substance selected from the group consisting of a gel matrix and polymer beads.

13. The kit of claim 1 , wherein the at least one immobilized binding partner comprises a reagent selected from the group consisting of a protein that specifically binds to the distinct peptide, and an antibody or antibody fragment that specifically binds a mutant signature peptide.

14. The kit of claim 1 , wherein the at least one immobilized binding partner is 1 to about 500 immobilized binding partners, wherein each immobilized binding partner specifically binds to a different distinct peptide.

15. The kit of claim 1 , wherein the at least one immobilized binding partner is at least 500 immobilized binding partners, wherein each immobilized binding partner specifically binds to a different distinct peptide.

16. The kit of claim 1 , wherein the kit further comprises an elution solution capable of causing the dissociation of the distinct peptide from the immobilized binding partner into the elution solution.

Assignees

• Cell Signaling Technology Inc

Inventors

• Moritz Albrecht
• Rush Ii John Edward
• Polakiewicz Roberto

Classifications

• B01D15/3823

  of other types, e.g. avidin, streptavidin or biotin · CPC title

• B01D15/422

  Displacement mode · CPC title

• G01N2560/00

  Chemical aspects of mass spectrometric analysis of biological material · CPC title

• G01N2570/00

  Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes · CPC title

• B01D15/325

  Reversed phase · CPC title